AGO2 and ovarian carcinoma: Moreover for ovarian cancer, they took into account liquid biopsy studies in the blood (plasma/serum), ascites or urine, involving all the cf-miRNAs, not only those transported by microvesicles, exosomes, or apoptotic bodies, but also those protected by RNA-binding protein such as Argonaute 2, or lipoprotein complexes.